EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
1.8.1.7 | (Z)-ajoene + NADPH + H+ |
- |
Homo sapiens |
4,5,9-trithiadodeca-1,6,11-triene + 4,8,9,13-tetrathiahexadeca-1,6,10,15-tetraene + NADP+ |
- |
r |
1.8.1.7 | 1,4-dihydroxy-9,10-anthraquinone + NADPH |
- |
Plasmodium falciparum |
? |
- |
? |
1.8.1.7 | 1,4-dihydroxy-9,10-anthraquinone + NADPH |
- |
Plasmodium falciparum FcB1 |
? |
- |
? |
1.8.1.7 | 1,4-naphthoquinone + NADPH + H+ |
- |
Homo sapiens |
? |
- |
? |
1.8.1.7 | 1,4-naphthoquinone + NADPH + H+ |
- |
Plasmodium falciparum |
? |
- |
? |
1.8.1.7 | 1,4-naphthoquinone + NADPH + H+ |
- |
Plasmodium falciparum FcB1 |
? |
- |
? |
1.8.1.7 | 1,8-dihydroxy-9,10-anthraquinone + NADPH |
- |
Plasmodium falciparum |
? |
- |
? |
1.8.1.7 | 2 ajoene + 4 NADPH + 4 H+ |
i.e. (E,Z)-4,5,9-trithiadodeca-1,6,11-triene-9-oxide, substrate and inhibitor |
Homo sapiens |
4,8,9,13-tetrathiahexadeca-1,6,1,15-tetraene + 4 NADP+ + 2 allylmercaptan |
- |
? |
1.8.1.7 | 2 ajoene + 4 NADPH + 4 H+ |
also formation of single-electron reduced product and concomitantly superoxide anion radicals |
Homo sapiens |
4,8,9,13-tetrathiahexadeca-1,6,1,15-tetraene + 4 NADP+ + 2 allylmercaptan |
- |
? |
1.8.1.7 | 2,3-dimethylquinoxaline-5,8-dione + NADPH + H+ |
- |
Homo sapiens |
? |
- |
? |